These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35063454)

  • 1. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
    Henriette Zweijpfenning SM; Chiron R; Essink S; Schildkraut J; Akkerman OW; Aliberti S; Altenburg J; Arets B; van Braeckel E; Delaere B; Gohy S; Haarman E; Lorent N; McKew G; Morgan L; Wagner D; van Ingen J; Hoefsloot W
    Chest; 2022 Jul; 162(1):76-81. PubMed ID: 35063454
    [No Abstract]   [Full Text] [Related]  

  • 2. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.
    Khan O; Chaudary N
    Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment for nontuberculous mycobacterial lung disease.
    Kang YA; Koh WJ
    Expert Rev Respir Med; 2016; 10(5):557-68. PubMed ID: 26967761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
    Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
    [No Abstract]   [Full Text] [Related]  

  • 5. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
    Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
    Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
    Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
    Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative antimicrobial susceptibilities for respiratory clinical isolates of
    Shakoor S; Shafiq S; Shahid A; Mir F; Ali R; Hasan R
    Int J Mycobacteriol; 2023; 12(3):310-315. PubMed ID: 37721238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
    Kang N; Jeon K; Kim H; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ; Jhun BW
    Chest; 2021 Aug; 160(2):436-445. PubMed ID: 33621600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.
    Takao D; Takeda K; Takazono T; Ozasa M; Ito Y; Ashizawa N; Hirayama T; Iwanaga N; Takemoto S; Ide S; Tashiro M; Hosogaya N; Kido T; Sakamoto N; Obase Y; Okano S; Izumikawa K; Yanagihara K; Mukae H
    J Infect Chemother; 2023 Aug; 29(8):806-808. PubMed ID: 37098378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease.
    Sawka A; Burke A
    Clin Chest Med; 2023 Dec; 44(4):815-828. PubMed ID: 37890918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Approaches to Mycobacterium abscessus Pulmonary Disease.
    Holt MR; Baird T
    Clin Chest Med; 2023 Dec; 44(4):785-798. PubMed ID: 37890916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of amikacin in the treatment of nontuberculous mycobacterial disease.
    Raaijmakers J; Schildkraut JA; Hoefsloot W; van Ingen J
    Expert Opin Pharmacother; 2021 Oct; 22(15):1961-1974. PubMed ID: 34292097
    [No Abstract]   [Full Text] [Related]  

  • 15. Nontuberculous mycobacteria infections in immunosuppressed hosts.
    Henkle E; Winthrop KL
    Clin Chest Med; 2015 Mar; 36(1):91-9. PubMed ID: 25676522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection.
    Rose SJ; Neville ME; Gupta R; Bermudez LE
    PLoS One; 2014; 9(9):e108703. PubMed ID: 25264757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epetraborole Is Active against Mycobacterium abscessus.
    Ganapathy US; Gengenbacher M; Dick T
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115621. PubMed ID: 34280020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
    Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
    Kwon YS; Daley CL; Koh WJ
    Expert Rev Respir Med; 2019 Sep; 13(9):851-861. PubMed ID: 31256694
    [No Abstract]   [Full Text] [Related]  

  • 20. Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.
    Senhaji-Kacha A; Akir A; Broncano-Lavado A; Esteban J
    Rev Esp Quimioter; 2024 Jun; 37(3):266-269. PubMed ID: 38602224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.